|Title:||Monitoring of 2-deoxy-2-[<sup>18</sup>F]fluoro-D-glucose uptake in tumor-bearing mice using high-sensitivity projection imaging: Compared with PET imaging||Authors:||Liao, M.-H.
|Keywords:||chemotherapeutic efficacy; high-throughput screening; microPET; murine tumor model; planar positron imaging system||Issue Date:||2010||Journal Volume:||31||Journal Issue:||12||Start page/Pages:||1040-1044||Source:||Nuclear Medicine Communications||Abstract:||
Objective: To investigate the feasibility of using high-sensitivity projection [18F]fluoro-deoxyglucose imaging to monitor chemotherapeutic efficacy in BALB/c mice bearing CT-26 tumor implants. Methods: A planar positron imaging system (PPIS)-4800 and a microPET R4 were used for projection and tomographic imaging, respectively. Six disks filled with different volumes of 18F-FDG solution were scanned by PPIS for calibration check. Tumor-bearing mice were treated with saline (control) or cyclophosphamide by intraperitoneal injections. Tumor responses were evaluated by both PPIS and microPET imaging. Results: The disk-activity ratios obtained from PPIS were 1.00: 1.30: 1.98: 2.48: 2.73: 3.53 with corresponding volume ratios of 1.0: 1.5: 2.0: 2.5: 3.0: 3.5. PPIS imaging in tumor-bearing mice showed that the tumor/non-tumor ratios were 1.62, 2.12, 3.03, 4.46, and 3.61 on days 7, 10, 13, 17, and 20, respectively, after tumor inoculation. In addition, PPIS was used to monitor the chemotherapeutic effect of cyclophosphamide on tumor-bearing mice. The correlation coefficients between the tumor sizes and tumor/non-tumor ratios for microPET and PPIS were 0.63 and 0.72, respectively, in the control group, and were 0.98 and 0.81, respectively, in the cyclophosphamide-treated group. Conclusion: This study showed that PPIS imaging is a feasible modality for monitoring tumor responses. These results suggest that PPIS, a potential high-throughput screening imaging system, may be used for the preclinical evaluation of tumor response to new anticancer drugs using murine tumor models. ? 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins.
|DOI:||10.1097/MNM.0b013e3283406ab3||SDG/Keyword:||2 deoxy 2 f 18; cyclophosphamide; fluorodeoxyglucose f 18; radiopharmaceutical agent; unclassified drug; animal cell; animal experiment; animal model; article; calibration; colon carcinoma; controlled study; drug effect; drug efficacy; drug monitoring; drug sensitivity; drug uptake; imaging system; male; mouse; nonhuman; planar positron imaging system; positron emission tomography; treatment response; tumor volume; Animals; Antineoplastic Agents; Biological Transport; Cell Line, Tumor; Colonic Neoplasms; Cyclophosphamide; Feasibility Studies; Fluorodeoxyglucose F18; Humans; Male; Mice; Phantoms, Imaging; Positron-Emission Tomography; Treatment Outcome; Xenograft Model Antitumor Assays
|Appears in Collections:||獸醫學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.